INESC-ID’s startup HeartGenetics – Genetics and Biotechnology, S.A. was recently acquired by ImpactLab, the largest genetic laboratory provider in Italy in oncology and pre-/post-natal genetic testing. By being part of ImpactLab group, HeartGenetics will be able to continue its expansion in the B2B business model and broaden the online business in Spain, Italy and South America.
Our researcher Ana Teresa Freitas, CEO and co-founder of HeartGenetics, will continue to serve as CEO of the company and will support the development of the Company and its integration with the ImpactLab group.
HeartGenetics will keep its own brand and will continue to serve its clients in Portugal, Brazil, Netherlands and Spain. The company will also have the opportunity to start sales in Italy.
“In 2013, we had the vision of creating a company that could use genetic data and computational tools to improve health for everybody. The acquisition of HeartGenetics by ImpactLab is an amazing and unique opportunity to build upon that vision, enhance our digital and bioinformatics capabilities, and deepen our roots in the personalized medicine field. For a startup in the diagnosis field, this acquisition represents a major achievement for the healthcare Portuguese startup ecosystem” stated Ana Teresa Freitas.